|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Riva2.5+DAPT | Total patients (n) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 706 | 　 |
| Major bleeding (%) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 1.9 | 　 |
| Major bleeding (n) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 12 | 　 |
| MACCEs (%) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 21.7 | 　 |
| MACCEs (n) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 143 | 　 |
| Riva15+P2Y12 | Total patients (n) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 61 | 696 | 　 |
| Major bleeding (%) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 9.8 | 2.1 | 　 |
| Major bleeding (n) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 6 | 14 | 　 |
| MACCEs (%) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 13.1 | 21.4 | 　 |
| MACCEs (n) | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 8 | 136 | 　 |
| VKA+SAPT | Total patients (n) | 　 | 279 | 　 | 　 | 51 | 73 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 31 |
| Major bleeding (%) | 　 | 3.2 | 　 | 　 | 9.8 | 6.8 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 6.45 |
| Major bleeding (n) | 　 | 9 | 　 | 　 | 5 | 5 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 2 |
| MACCEs (%) | 　 | 11.1 | 　 | 　 | 37.3 | 17.8 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 12.9 |
| MACCEs (n) | 　 | 31 | 　 | 　 | 19 | 13 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 4 |
| DAPT | Total patients (n) | 103 | 　 | 60 | 1200 | 67 | 162 | 166 | 236 | 3589 | 488 | 266 | 130 | 　 | 　 | 19 |
| Major bleeding (%) | 1.94 | 　 | 6.9 | 11.9 | 4.5 | 12.3 | 0.6 | 4.6 | 11.0 | 11.5 | 2.3 | 2.4 | 　 | 　 | 5.3 |
| Major bleeding (n) | 2 | 　 | 4 | 154 | 3 | 33 | 6 | 11 | 395 | 56 | 35 | 21 | 　 | 　 | 1 |
| MACCEs (%) | 15.5 | 　 | 3.3 | 20.7 | 29.9 | 20.4 | 19.3 | 17.8 | 32.7 | 20.1 | 18.4 | 21.5 | 　 | 　 | 21.1 |
| MACCEs (n) | 2 | 　 | 4 | 143 | 3 | 20 | 1 | 11 | 395 | 56 | 6 | 3 | 　 | 　 | 1 |
| TT | Total patients (n) | 14 | 284 | 44 | 448 | 28 | 679 | 37 | 131 | 1370 | 371 | 319 | 159 | 92 | 697 | 48 |
| Major bleeding (%) | 0 | 5.6 | 11.1 | 14.4 | 21.4 | 10.2 | 2.7 | 16.7 | 17.6 | 6.4 | 7.5 | 11.7 | 6.5 | 3.3 | 8.3 |
| Major bleeding (n) | 0 | 16 | 5 | 64 | 6 | 69 | 1 | 22 | 241 | 24 | 24 | 19 | 6 | 20 | 4 |
| MACCEs (%) | 7.14 | 17.6 | 11.4 | 19.6 | 25.0 | 21.6 | 2.7 | 22.1 | 32.6 | 17.0 | 15.4 | 18.2 | 25.0 | 29.3 | 27.1 |
| MACCEs (n) | 1 | 50 | 5 | 88 | 7 | 147 | 1 | 29 | 447 | 63 | 49 | 29 | 23 | 175 | 13 |
| Trial/country | Germany | WOEST  | Poland | CRUSADE | Japan | AFCAS | Korea Suh | Korea Kang | ACTION  | AVIATOR | Spain | Triple Elderly  | ROCKET-AF  | PIONEER AF-PCI | Italy |
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |